SCHEDULE 13G/A: Vanguard Group Discloses 9.62% Stake in SpringWorks Therapeutics

The Vanguard Group has filed an amended Schedule 13G, reporting a 9.62% beneficial ownership stake in SpringWorks Therapeutics Inc. as of December 31, 2024.

Summary

• The Vanguard Group, an investment adviser based in Malvern, PA, has filed an Amendment No. 3 to Schedule 13G regarding its beneficial ownership in SpringWorks Therapeutics Inc.
• As of December 31, 2024, Vanguard beneficially owns an aggregate of 7,158,871 shares of SpringWorks Therapeutics Inc. Common Stock.
• This ownership represents 9.62% of the class of securities.
• Vanguard holds sole voting power over 0 shares, shared voting power over 127,323 shares, sole dispositive power over 6,955,440 shares, and shared dispositive power over 203,431 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing (Schedule 13G/A) reporting beneficial ownership. It does not contain information that would inherently be positive or negative, but rather provides factual data on an institutional holding. The sentiment is neutral as it's an expected disclosure from a passive investor.

Future Outlook

NA

Industry Context

This filing indicates a significant institutional investment by The Vanguard Group in SpringWorks Therapeutics, a biotechnology company. Such large passive stakes by major asset managers like Vanguard are common and reflect their broad market index strategies or active fund allocations within the pharmaceutical and biotechnology sectors. It does not inherently signal a specific industry trend but rather a continued presence of institutional capital in the biotech space.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence market perception and liquidity.
• Company Management: Awareness of a large, passive institutional holder, which typically does not seek to influence control but represents a stable part of the shareholder base.

Key Dates

Keywords

SpringWorks Therapeutics, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals